Does plasma neurofilament light chain predict progression in progressive supranuclear palsy?
Plasma NfL is elevated in PSP and could be of value as a biomarker both to assist clinical diagnosis and to monitor pharmacodynamic effects on the neurodegenerative process in clinical trials.
Our results suggest that MAT1A genotypes appear to modulate effects of dietary fat on plasma Hcy.